aTyr Pharma
ATYR
46 hedge funds and large institutions have $262M invested in aTyr Pharma in 2015 Q2 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$78.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$51.8M |
| 3 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
+$40.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.4M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$18.6M |
Top Sellers
ATYR Hedge Fund Activity: Q2 2015 in Review
46 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2015, worth a combined $262M.
Buyers outnumbered sellers: 46 funds opened new ATYR positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $78.6M.
- 46 institutional investors held aTyr Pharma (ATYR) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $262M of aTyr Pharma stock for Q2 2015.
- 46 funds opened new aTyr Pharma positions in Q2 2015 and 0 closed out, a net change of +46 holders.
- The largest aTyr Pharma buyer in Q2 2015 was Fidelity Investments, an estimated $78.6M added.
Based on aggregated 13F filings for Q2 2015.